Cargando…
Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?
Studies using monoclonal antibody MR6, which is thought to bind to the interleukin-4 growth factor receptor (IL-4R), indicate that IL-4R molecules are upregulated in tumours of epithelial origin and that radiolabelled MR6 is effective as an in vivo tumour imaging agent. Immunohistochemical analysis...
Autores principales: | Al Jabaari, B., Ladyman, H. M., Larché, M., Sivolapenko, G. B., Epenetos, A. A., Ritter, M. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246718/ https://www.ncbi.nlm.nih.gov/pubmed/2736228 |
Ejemplares similares
-
Immunosuppression by immunoglobulin deaggregation is not effective in reducing the anti-xenogeneic immunoglobulin response: experimental and clinical studies.
por: Sivolapenko, G. B., et al.
Publicado: (1989) -
Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate.
por: Sivolapenko, G. B., et al.
Publicado: (1991) -
A recombinant single chain antibody interleukin-2 fusion protein.
por: Savage, P., et al.
Publicado: (1993) -
Interleukin-4 receptor targeted immunotherapy of human bladder cancer in animal models
por: Joshi, Bharat H, et al.
Publicado: (2014) -
Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy
por: Sengupta, Sadhak, et al.
Publicado: (2014)